Aclaris Therapeutics Inc (NASDAQ:ACRS) currently has a daily average trading volume of 1.98M but it saw 2961628 shares traded in last market. With a market cap of 308.58M USD, the company’s current market price of $4.32 came rising about 9.09 while comparing to the previous closing price of $3.96. In past 52 weeks, the stock remained buoying in the range of price level as high as $5.17 and as low as $0.77. In the recent trading on the day, stock has struck highest price mark of $4.07 while lowest mark touched by it was $4.55.
Taking a look at 20-day trading activity of Aclaris Therapeutics Inc (ACRS) gives us an average price of $2.52, while its current price level is -16.44% below from 52-week high level whereas it is 461.04% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.72 while that of 200 days or SMA-200 reads an average of $1.34. A closer look into the stock’s movement over the week reveals that its volatility is standing at 28.06% during that period while stretching the period over a month that decreases to 16.73%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 74.71 which implies that the stock is in overbought territory.
Leerink Partners upgraded its recommendation for the stock as a “Outperform” from “Market Perform” on November 19, 2024 while assigning a price target range of $2-$7. Jefferies also issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $2 and $7.
Over the week, ACRS’s stock price is moving 98.17% up while it is 242.86% when we observe its performance for the past one month. Year-to-date it is 311.43% up and over the past year, the stock is showing an upside performance of 385.34%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.02 beat the consensus estimate of -0.39 for the same. The company is expected to be releasing its next quarterly report in December, for which analysts forecasted an EPS of -0.27 while estimate for next year EPS is -0.75. In next quarter, company is expected to be making quarterly sales of $3.25M as analysts are expecting the sales for current fiscal year at $15.79M and seeing the company making $12.04M in sales next year. Moreover, analysts are in estimates of $5.85M for current-quarter revenue.
Currently, Aclaris Therapeutics Inc’s total number of outstanding shares is 70.89M with 2.66% of that held by the insiders while 73.53% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -27.95% and return on equity (ROE) at -25.83%. Stock’s beta reads 0.31. Stock has a price to book (P/B) ratio of 2.37 while price to sale or P/S ratio amounts to 11.40. Its return on asset (ROA) is -18.47% on average.
